

Prima BioMed – Fast Facts

Listings

Australian Securities Exchange (ASX), NASDAQ

Stock Codes

ASX: PRR, NASDAQ: PBMD

Issued Capital – Ordinary shares

2.36 billion (as of October 22, 2017)

Market Capitalisation

A\$68.52 million (US\$53.75 million) (as of October 22, 2017)

Issued ADR's

7.4 million (as of Sep 30, 2017)

Cash & Term Deposits

~A\$17.0 million (~US\$13.3 million) (as of Sep 30, 2017)

Board of Directors

Ms Lucy Turnbull, AO Chairman (Non-Executive)

Mr Albert Wong Deputy Chairman (Non-Executive)

Mr Marc Voigt Executive Director, Chief Executive Officer

Mr Russell J Howard, Ph.D. Non-Executive Director

Mr Pete A Meyers Non-Executive Director

Mr Grant Chamberlain Non-Executive Director

Senior Management

Prof Frédéric Triebel, Ph.D. MD Chief Scientific Officer & Chief Medical Officer

Deanne Miller Chief Operating Officer, General Counsel & Company Secretary

Company Overview

Prima BioMed Ltd. (ASX:PRR, NASDAQ: PBMD) is a globally active biotechnology company developing novel immunotherapeutic products for cancer and autoimmune diseases.

With operations based in Australia, Germany, France and the U.S., Prima BioMed is dedicated to bringing innovative treatment options to the market for patients and to maximizing value for shareholders.

Prima's core technologies are based on the **LAG-3** immune control mechanism which plays a vital role in the regulation of the T cell immune response.

Our lead product candidate **IMP321** is in clinical development for the treatment of a range of cancer indications.


IMP321 is being tested in the AIPAC (**A**ctive **I**mmunotherapy **P**AClitaxel) clinical trial, a chemo-immunotherapy combination in a Phase II randomized, double-blind, placebo-controlled study in metastatic breast cancer. In the combinatorial study TACTI-mel (**T**wo **A**ctive **I**mmunotherapeutics in **m**elanoma) IMP321 is being evaluated in combination with an immune checkpoint inhibitor in metastatic melanoma.

IMP761, Prima's latest product candidate, is an agonist antibody against LAG-3 that is in preclinical development and is expected to be developed for autoimmune diseases.

In addition, in July the Institute of Clinical Cancer Research, Krankenhaus Nordwest GmbH in Frankfurt Germany ("IKF"), Prima's collaboration partner, received the regulatory and ethical approvals to begin the clinical trial investigating IMP321 in new settings, called "INSIGHT". The investigator sponsored INSIGHT clinical trial will explore different routes of administration of IMP321 in solid tumours.

Three of our products have been partnered with large pharmaceutical partners including Eddingpharm, GSK and Novartis.

LAG-3/ MHC class II interaction



- **Positive regulation of** 
antigen presenting cells (APC) → increase in antigen presentation to cytotoxic CD8⁺ T cells (primary MoA)
- **Negative regulation of** 
LAG-3⁺ T cells (Secondary MoA)

Prima Contact Information


Headquarters

Level 12, 95 Pitt Street
 Sydney, NSW 2000, Australia

enquiries@primabiomed.com.au
 partnering@primabiomed.com.au

www.primabiomed.com.au

Pipeline




*Expected timing of data readouts. Actual results may differ.

**INSIGHT clinical trial controlled by lead investigator and therefore Prima has no control over this clinical trial

Lead Target: LAG-3

Targeting of LAG-3 leads to multiple therapeutics in numerous indications



IMP321 is a recombinant protein consisting of a dimer of LAG-3 that has been engineered to be soluble rather than expressed on the surface of cells.

IMP321 works as an **immune stimulator** as it is a first-in-class antigen presenting cell (APC) activator to induce sustained immune cell responses. This application is promising in immuno-oncology therapies and as therapies against viral infections.

In order to reduce immune cell responses, the binding of an agonist mAb like IMP761 or a depleting mAb like IMP731 to LAG-3 on activated autoreactive T-cells can be a promising **immunosuppression** therapy in autoimmune diseases.

For detailed information about the mode of action please refer to the video on our website and the following link below:

<https://www.youtube.com/embed/MKAdIMc25uc>

Lead Technology: LAG-3 (Lymphocyte Activation Gene-3 / LAG-3 or CD223)

LAG-3 is involved in the regulation of T cells. It has a dual mechanism of action and controls the signaling between T cells and antigen presenting cells (APC's).

Forward looking statements: Any forward looking statements in this fact sheet have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside Prima BioMed Ltd.'s control. Additionally, the INSIGHT investigator sponsored clinical trial described in this fact sheet is controlled by the lead investigator and therefore Prima has no control over this clinical trial. This fact sheet should not be relied on as a recommendation or forecast by Prima BioMed. Nothing in this fact sheet should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.